Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The protein kinase B-RAF is a human oncogene that is mutated in ∼70% of human melanomas and transforms mouse melanocytes. Microphthalmia-associated transcription factor (MITF) is an important melanocyte differentiation and survival factor, but its role in melanoma is unclear. In this study, we show that MITF expression is suppressed by oncogenic B-RAF in immortalized mouse and primary human melanocytes. However, low levels of MITF persist in human melanoma cells harboring oncogenic B-RAF, suggesting that additional mechanisms regulate its expression. MITF reexpression in B-RAF–transformed melanocytes inhibits their proliferation. Furthermore, differentiation-inducing factors that elevate MITF expression in melanoma cells inhibit their proliferation, but when MITF up-regulation is prevented by RNA interference, proliferation is not inhibited. These data suggest that MITF is an antiproliferation factor that is down-regulated by B-RAF signaling and that this is a crucial event for the progression of melanomas that harbor oncogenic B-RAF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MITF protein expression is suppressed by BRAFV600E in melanocytes and melanomas, however, which allows cell proliferation48,56.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 6×
“5 D, lanes 1, 2, 5, and 6) and in two melanoma cell lines that express oncogenic B-RAF (Davies et al., 2002), and this is accompanied by reduced proliferation (Fig.”
BackgroundInfluentialSelf-citationThe RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228 · cited 8×
“Cells were transfected as described previously (Wellbrock et al., 2004b) using 20–120 nM A-RAF, C-RAF, scrambled (Karasarides et al., 2004), B-RAF (5 -AACAGUCUACAAGGGAAAGUG-3 ), or melanocyte-specific”
BackgroundMethodInfluentialSelf-citationMcGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760 · cited 2×
“We propose that MITF function cannot be completely abolished in melanoma and that low level expression must be maintained to stimulate survival and/or proliferation, possibly by regulating BCL2 (McGill et al., 2002) and CDK2 (Du et al., 2004) expression.”
BackgroundMAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 630 · cited 3×
“2 B); these effects were previously attributed to ERK-dependent phosphorylation on S73 (Hemesath et al., 1998).”
BackgroundMethodInfluentialWu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 527 · cited 7×
“Previous studies have shown that ERK phosphorylates S73 of MITF, targeting it for degradation (Wu et al., 2000; Xu et al., 2000), so we analyzed whether this mechanism underlies MITF loss in our cell lines.”
BackgroundResultInfluentialMicrophthalmia Gene Product as a Signal Transducer in cAMP-Induced Differentiation of Melanocytes
Bertolotto, C., Abbe, P., Hemesath, T. J., Bille, K., Fisher, D. E., Ortonne, J.-P., & Ballotti, R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.142.3.827 · Cited by 512 · cited 4×
“For example, the differentiation factor -melanocyte–stimulating hormone strongly increases its expression in a cAMP and cAMP response element binding protein (CREB) transcription factor–dependent manner (Bertolotto et al., 1998).”
BackgroundInfluentialSuppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426 · cited 6×
“Cells were transfected as described previously (Wellbrock et al., 2004b) using 20–120 nM A-RAF, C-RAF, scrambled (Karasarides et al., 2004), B-RAF (5 -AACAGUCUACAAGGGAAAGUG-3 ), or melanocyte-specific”
BackgroundMethodInfluentialSelf-citationDu, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421 · cited 2×
“Importantly, forskolin-induced MITF expression (Fig.”
BackgroundDown-regulation of the novel gene melastatin correlates with potential for melanoma metastasis.
Duncan, L. M., Deeds, J. D., Hunter, J., Shao, J., Holmgren, L. M., Woolf, E. A., Tepper, R. I., & Shyjan, A. W. (1998) · PubMed · Cited by 401
Cited by
Items 101–200 of 206
Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells
Pathria, G., Garg, B., Borgdorff, V., Garg, K., Wagner, C., Superti‐Furga, G., & Wagner, S. N. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.369 · Cited by 26
“These molecular events suggested a MITF-mediated antiproliferative program.(20) However, the observed AURKA-i-”
BackgroundInfluentialRecent discoveries in the genetics of melanoma and their therapeutic implications
Marquette, A., Bagot, M., Bensussan, A., & Dumaz, N. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0043-5 · Cited by 24
Melanoma Suppressor Functions of the Carcinoma Oncogene FOXQ1
Bagati, A., Bianchi, A., Moparthy, S., Kolesnikova, K., Fink, E. E., Lipchick, B. C., Kolesnikova, M., Jowdy, P., Polechetti, A., Mahpour, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.057 · Cited by 23
“, 2005), a significant body of literature demonstrates that strong downregulation of MITF, sometimes even below detection, correlates with poor prognosis and disease progression in patients (Carreira et al., 2006a; Salti et al., 2000; Selzer et al., 2002; Wellbrock and Marais, 2005).”
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF
Gutierrez-Prat, N., Zuberer, H. L., Mangano, L., Karimaddini, Z., Wolf, L., Tyanova, S., Wellinger, L. C., Marbach, D., Griesser, V., Pettazzoni, P., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101235 · Cited by 21
“It has been previously reported that RAF and MEK inhibitors can increase the expression of MITF and MITF targets in human melanoma cell lines (24, 25, 26).”
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions
Andersen, J. B., & Thorgeirsson, S. S. (2013) · Hepatic Oncology · doi:10.2217/hep.13.4 · Cited by 21
Crosstalk signaling in targeted melanoma therapy
Meierjohann, S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9659-z · Cited by 21
“, by increasing MITF turnover or regulating its transcription [42, 43].”
BackgroundValcárcel-Jiménez, L., Macchia, A., Martín-Martín, N., Cortázar, A. R., Schaub-Clerigué, A., Pujana-Vaquerizo, M., Fernández‐Ruiz, S., Lacasa-Viscasillas, I., Santos-Martín, A., Loizaga‐Iriarte, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1096-6 · Cited by 24
Growth Factors and Oncogenes as Targets in Melanoma: Lost in Translation?
Kwong, L. N., Chin, L., & Wagner, S. N. (2007) · Advances in Dermatology · doi:10.1016/j.yadr.2007.07.015 · Cited by 24
Aiswarya, S. U. D., Vikas, G., Haritha, N. H., Liju, V. B., Shabna, A., Swetha, M., Rayginia, T. P., Keerthana, C. K., Nath, L. R., Reshma, M. V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903832 · Cited by 22
“In melanoma cells harboring B-RAF mutation, MITF-M down-regulated by B-RAF signaling is considered a crucial event for the progression of melanoma (34).”
BackgroundHypoxia-Independent Drivers of Melanoma Angiogenesis
Meierjohann, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00102 · Cited by 20
“High MITF activity, however, promotes differentiation and exit from the cell cycle (44, 45).”
Cho, B.-R., Jun, H., Thach, T. T., Wu, C., & Lee, S. (2017) · Food Science and Biotechnology · doi:10.1007/s10068-017-0171-6 · Cited by 18
Noguchi, K., Dincman, T. A., Dalton, A. C., Howley, B. V., McCall, B. J., Mohanty, B. K., & Howe, P. H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003616 · Cited by 18
“At a molecular level, MEK signaling affects many transcription factors including the basic-helix-loop-helix leucine zipper (bHLH LZip) transcription factor micropthalmia-associated transcription factor (MITF) (3, 7).”
BackgroundInfluentialOvercoming Resistance to Apoptosis in Cancer Therapy
Hersey, P., Zhang, X. D., & Mhaidat, N. M. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_6 · Cited by 19
Immunohistochemical profile of oral mucosal and head and neck cutaneous melanoma
Alaeddini, M., & Etemad‐Moghadam, S. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12235 · Cited by 17
Nishimura, K., HIROKAWA, Y. S., Mizutani, H., & Shiraishi, T. (2006) · PubMed · Cited by 17
Monroe, J. D., Basheer, F., & Gibert, Y. (2021) · Cells · doi:10.3390/cells10051132 · Cited by 14
“Similarly, in mouse and human melanocytes, B-Raf acts to suppress MITF signaling via ERK and promote proliferation, while upregulation of MITF prevents proliferation through the cAMP pathway [93].”
BackgroundShabna, A., Antony, J., Vijayakurup, V., Saikia, M., Liju, V. B., Retnakumari, A. P., Amrutha Nisthul, A., Alex, V. V., Swetha, M., Aiswarya, S. U. D., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04476-y · Cited by 16
Rad6 is a Potential Early Marker of Melanoma Development
Rosner, K., Adsule, S., Haynes, B. M., Kirou, E., Kato, I., Mehregan, D. R., & Shekhar, M. P. V. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.04.009 · Cited by 13
“Mitf is down-regulated in B-raf transformed murine melanocytes and B-raf overexpressing human melanocytes, and exogenous reexpression of Mitf inhibited the proliferation of these cells [44].”
BackgroundThe Impact of MITF on Melanoma Development: News from Bench and Bedside
Roider, E., & Fisher, D. E. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.390 · Cited by 12
Wang, Y., Li, M., Zeng, J., Yang, Y., Li, Z., Hu, S., Yang, F., Wang, N., Wang, W., & Tie, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1008195 · Cited by 11
“(46) found that the S73A mutation has no effect on MITF protein stability, in line with our results.”
ResultKükenshöner, T., Wohlwend, D., Niemöller, C., Dondapati, P., Speck, J., Adeniran, A., Nieth, A., Gerhardt, S., Einsle, O., Müller, K. M., et al. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.03.002 · Cited by 10
“, 2009), it is still under debate whether MITF is a driving proto-oncogene (Palmieri et al., 2009; Wellbrock and Marais, 2005).”
BackgroundXu, Y., Guo, X., Sun, J., & Zhao, Z. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu603 · Cited by 9
“Previous studies reported that BRAF and NRAS promote gene expression of MITF mediated via MAPK pathway (Bollag et al., 2010; Garraway et al., 2005; Nazarian et al., 2010; Wellbrock and Marais, 2005; Yokoyama et al., 2011).”
BackgroundInfluentialRecent advances in melanoma research
Jon, A. R. (2006) · Frontiers in bioscience · doi:10.2741/2028 · Cited by 9
“Overexpression of BRAF can suppress MITF expression via ERK-induced degradation, whereas its reintroduction inhibits proliferation of human melanocytes (76).”
BackgroundRossi, E. D., Martini, M., Bizzarro, T., Schmitt, F. C., Longatto‐Filho, A., & Larocca, L. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12564 · Cited by 10
“Given that, the activation of the BRAF/MAPK pathway may suppress levels of MITF and PGC1α and decrease oxidative metabolism [14, 72].”
BackgroundResultInfluentialMitf silencing cooperates with IL-12 gene transfer to inhibit melanoma in mice
Nakai, N., Kishida, T., Hartmann, G., Katoh, N., Imanishi, J., Kishimoto, S., & Mazda, O. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2009.12.015 · Cited by 9
Vučinić, D., Grahovac, M., Grahovac, B., Mohar, B., Kovač, L., Belušić-Gobić, M., & Zamolo, G. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153725 · Cited by 8
Research progress on peptides that inhibit melanin synthesis
Yu, B., Wang, N., Cai, S., Yan, H., Sun, S., Wang, S., Li, Y., & Liang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610623 · Cited by 11
Pinto, R., Summa, S. D., Strippoli, S., Pilato, B., Azzariti, A., Guida, G., Guida, M., & Tommasi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7175 · Cited by 7
“In fact it has been shown that the hyper-activation of RAS-RAF-MEK-ERK signalling causes a significant reduction in MITF levels and therefore melanocytes and melanoma cells proliferation [35].”
Aebischer, V., Abu‐Ghazaleh, A., Metzler, G., Riedl, L., Garbe, C., Flatz, L., Eigentler, T., & Forchhammer, S. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13114 · Cited by 7
“However, MITF appears to suppress proliferation, as well as melanocyte and melanoma invasion (Carreira et al., 2006; Du et al., 2004; Hoek et al., 2006; Wellbrock & Marais, 2005).”
BackgroundNaffouje, S. A., Naffouje, R., Chen, J., & Salti, G. I. (2016) · Anticancer Research · doi:10.21873/anticanres.11266 · Cited by 8
The use of hormonal therapy in pediatric heart disease
Nathan, B. M. (2009) · Frontiers in Bioscience-Elite · doi:10.2741/e31 · Cited by 7
Reactive Oxygen Species in the Biology of Melanoma
Irene, L., Notcovich, C., Lucia, L., & Dura, H. (2011) · InTech eBooks · doi:10.5772/20003 · Cited by 6
“In another report, however, MiTF was downregulated in Braf-transformed murine melanocytes and BRAF-expressing human melanocytes; reexpression of MiTF in these cells inhibited cell proliferation (Wellbrock & Marais, 2005).”
BackgroundPocket protein function in melanocyte homeostasis and neoplasia
Tonks, I. D., Hayward, N. K., & Kay, G. F. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00321.x · Cited by 6
Targeted Therapies in Melanoma: Successes and Pitfalls
Palmieri, G., Colombino, M., Cristina, M., Ascierto, P. A., Lissia, A., & Cossu, A. (2013) · InTech eBooks · doi:10.5772/53624 · Cited by 9
“It has been shown that constitutive ERK ac‐ tivity, stimulated by V600EBRAF in melanoma cells, is associated with MITF ubiquitindependent degradation [60].”
BackgroundBRAF Mutation in Melanoma and Dietary Polyphenols as Adjunctive Treatment Strategy
Aquilato, A., López, V. V., Doonan, B. B., Hsieh, T., Pinto, J. T., Wu, E., & WU, J. M. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00102-x · Cited by 8
Stueven, N. A., Schlaeger, N. M., Monte, A. P., Hwang, S. L., & Huang, C. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.10.008 · Cited by 6
Keser, M., & Atmaca, H. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-03923-6 · Cited by 4
“Ectopic expression of BRAFV600E in human melanocytes has been shown to decrease the levels of MITF protein [20].”
Early diagnosis of melanoma: what do we know?
Yee, E., Hoffman, R. M., & Berwick, M. (2007) · Cited by 4
Molecular Pathogenesis of Melanoma: Established and Novel Pathways
Ascierto, P. A., Ascierto, M. L., Capone, M., Elaba, Z., Murphy, M. J., & Palmieri, G. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_3 · Cited by 3
“in melanoma cells, is associated with ubiquitindependent degradation of MITF [ 94 ] .”
BackgroundPasseron, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-10897-1_1 · Cited by 3
[Transcription factors in the development and progression of melanoma].
Lesiak, K., Sztiller-Sikorska, M., & Czyż, M. (2007) · PubMed · Cited by 5
Melanoma Genetics: From Susceptibility to Progression
Francisco, G., Cirilo, P. D. R., Toledo, F., Tortelli, T. C., & Chammas, R. J. (2013) · InTech eBooks · doi:10.5772/54143 · Cited by 3
“Regarding BRAF mutation, the most prevalent V600E (found in about 40% of melanomas – [14]), shows a transversion of thymine substitut‐ ed by adenine.”
BackgroundInfluentialVella, L. J., Andrews, M. C., Behren, A., Cebon, J. S., & Woods, K. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.929943 · Cited by 2
“BRAF downregulates microphthalmiaassociated transcription factor by stimulating its degradation, but conversely increases its BRN2-mediated transcription [51,52].”
BackgroundŠamija, I., Lukač, J., & Kusić, Z. (2010) · Acta Medica Academica · Cited by 3
Molecular spectrum of pigmented skin lesions: from nevus to melanoma
Jiang, H. L., Wortsman, J., Matsuoka, L. Y., Granese, J., Carlson, J. A., Mihm, M. C., & Slominski, A. T. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.5.679 · Cited by 2
Lineage specific core-regulatory circuits determine gene essentiality in cancer cellsPreprint
Rauscher, B., Henkel, L., Heigwer, F., & Boutros, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/609552 · Cited by 3
“Again, we took melanoma cells as an example to explore this hypothesis since the mechanisms of aberrant MITF activation have been carefully studied in the past (Garraway et al., 2005; Levy et al., 2006; Wellbrock and Marais, 2005; Wellbrock et al., 2008).”
BackgroundMolecular Pathology of Melanocytic Skin Cancer
Palmieri, G., Sarantopoulos, G. P., Barnhill, R. L., & Cochran, A. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7357-2_4 · Cited by 1
Dual Function of Wnts in Human Cutaneous Melanoma
Kulikova, K., Кибардин, А. В., Gnuchev, N. V., Georgiev, G. P., & Lari, S. (2011) · InTech eBooks · doi:10.5772/23354 · Cited by 1
“A high level of MITF activity restricts cell division, whereas a low level is associated with proliferation (Carreira et al., 2005, 2006; Loercher et al., 2005; Wellbrock & Marais, 2005).”
Melanoma and Other Skin Cancers
Paraiso, K. H. T., John, J. K., & Smalley, K. S. M. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_17 · Cited by 1
Targeting BRAF Activity as a Novel Paradigm for Melanoma Therapy
Smalley, K. S. M., & Flaherty, K. T. (2008) · CRC Press eBooks · doi:10.3109/9781420020328.006 · Cited by 1
Molecular Pathology and Testing in Melanocytic Tumors
Hedayat, A. A., Yan, S., & Tsongalis, G. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800886-7.00025-x · Cited by 1
Molecular pathology and testing in melanocytic tumors
Sriharan, A., & Yan, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00042-0 · Cited by 2
Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
Ballesteros‐Álvarez, J., & Blázquez‐Medela, A. M. (2024) · DNA · doi:10.3390/dna4040025 · Cited by 1
Molecular-Targeted Therapy for Melanoma
RUSSO, A. E., Bevelacqua, Y., Marconi, A., Veronesi, A., & Libra, M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_20 · Cited by 1
Regulation of Forkhead BOX O tumor suppressors by Reactive Oxygen Species
de Keizer, P. L. J. (2009) · Utrecht University Repository (Utrecht University) · Cited by 1
The biology and oncology of RAF–ERK signaling
Emuss, V., & Marais, R. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50019-7 · Cited by 3
Self-citationThe new melanoma: a novel model for disease progression
Schlegel, N. C. (2008) · ETH Zürich Research Collection · doi:10.3929/ethz-a-005593522
Role of checkpoint kinase 1 in malignant melanoma
Smith, J. (2013) · Enlighten: Theses (The University of Glasgow)
Targeting BRAF/MEK in melanoma: new hope or another false dawn?
Smalley, K. S. M., Herlyn, M., & Flaherty, K. T. (2007) · Expert Review of Dermatology · doi:10.1586/17469872.2.2.179 · Cited by 1
Molecular genetics and targeted therapies for cutaneous melanoma
Flaherty, K. T. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.04.011
Somatic genetics and targeted therapies for cutaneous melanoma
Flaherty, K. T., & Smalley, K. S. M. (2008) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2008.06.001
MITF (microphthalmia-associated transcription factor)
Riddle, N., & Zhang, P. (2013) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/51811
Role of retinoid mediated microphthalmia-associated transcription factor (MITF) in melanoma
Basak, T. K. (2012) · International Journal of Medicine and Medical Sciences · doi:10.5897/ijmms11.126
“MITF re-expression in BRAF transformed melanocytes inhibits their proliferation (Wellbrock and Marais, 2005).”
BackgroundThe Role of SWI/SNF Chromatin Remodeling Complex in Melanoma
Keenen, B. (2010) · OhioLink ETD Center (Ohio Library and Information Network)
The effects of siRNA-mediated knockdown of MITF and AP-2a in melanoma
Sundmark, E. B. (2015) · NVA (Nasjonalt vitenarkiv)
Augustine, C. K., Freedman, J. A., Beasley, G. M., & Tyler, D. S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00066-5
Rôle de NRAS et PTEN au cours de la mélanomagenèse
Longvert, C. (2012) · theses.fr (ABES) · doi:10.70675/d3f1dbaaz7676z4806z9cdbzc42907600eee
Pharmacie, F. D. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Pigmentation Pathways and Microphtalmia-Associated Transcription Factor as New Targets in Melanoma
Haq, R., & Fisher, D. E. (2008) · CRC Press eBooks · doi:10.3109/9781420020328-8
MiTF Regulates Cellular Response to Reactive Oxygen Species through Transcriptional Regulation of
Fu, Y., & Meyskens, F. L. (2009)
Ayyıldız, Z. Ö. (2014) · Bilkent University Institutional Repository (Bilkent University)
7-Piperazinethylchrysin inhibits melanoma cell proliferation by targeting Mek 1/2 kinase activity
Zeng, N., Qiu, H. Y., Lian, X., Ren, Y., Xu, Y., Wu, Y., Tang, H., & Wang, H. (2017) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v16i6.4
“Studies have shown that, among melanoma cells, more than 60 % harbor an activating mutation that induces Mek and Erk activation and consequently promotes the proliferation of cells and inhibits pigmentation [17].”
BackgroundMolecular Basis for Treating Cutaneous Melanoma
Ernstoff, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00042-1 · Cited by 1
Characterisation and regulation of the Egfr-Egfr ligand system in fish models for melanoma
Laisney, J. A. G. C. (2010) · Online Publication Service of Würzburg University (Würzburg University)
Rôle de MITF et du métabolisme des sphingolipides dans le mélanome cutané
Leclerc, J. (2019) · theses.fr (ABES) · doi:10.70675/e6ceb3b4z96a2z4196za809z97cd83844103
de Gruijl, F. R. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1159046.619333
Felicetti, F., Errico, M. C., Bottero, L., Segnalini, P., Stoppacciaro, A., Biffoni, M., Felli, N., Mattia, G., Petrini, M., Colombo, M. P., et al. (2023) · doi:10.1158/0008-5472.c.6498359
Felicetti, F., Errico, M. C., Bottero, L., Segnalini, P., Stoppacciaro, A., Biffoni, M., Felli, N., Mattia, G., Petrini, M., Colombo, M. P., et al. (2023) · doi:10.1158/0008-5472.c.6498359.v1
Popovic, A. (2021) · theses.fr (ABES) · doi:10.70675/7d530d71zf67az40a6z8295z2fa586dd1079 · Cited by 3
Characterization of the mechanisms of action of the transcription factor ZEB1 in melanoma
Tang, Y. (2021) · theses.fr (ABES) · doi:10.70675/d147bc89z14e4z4137zadecz307fd2f27136
Wang, Z., Li, J., Xu, J., Wan, T., Ya, Y., Li, X., Wang, X., & Jin, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02472-9
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma
Augustine, C., Jung, S., Potti, A., Sohn, I., Yoo, J., Zipfel, P. A., Olson, J. A., Ali‐Osman, F., Nevins, J. R., & Tyler, D. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9077
Régulation de l'expression du facteur de transcription Brn-2 dans les cellules de mélanomes
Bonvin, E. (2011) · theses.fr (ABES) · doi:10.70675/5e5274dezc58ez418az9dfbz1a4309204eb7
Signalisation et oncogenèse dans le mélanome
Marquette, A. (2009) · theses.fr (ABES) · doi:10.70675/738ddee8z26daz41b5zb0f8z345ff2ff8a05
Strub, T. (2012) · theses.fr (ABES) · doi:10.70675/25b97242za449z4aa4za428z86c8bf3f6bd2
Rôles et modes d'action de l'annexine A1 dans la dissémination du mélanome cutané
Boudhraa, Z. (2013) · theses.fr (ABES) · doi:10.70675/42602cd9zf60bz4a83z99dez170237ac6483
“Le variant BRAF (V600E) est retrouvé dans plus de 80% des nævi dysplasiques bénins suggérant que cette mutation représente l’un des premiers événements de la néoplasie mélanocytaire (35).”
InfluentialAllouche, J. (2015) · theses.fr (ABES) · doi:10.70675/5606d3e0z3de8z4075z8d8fzd73f0edd20de · Cited by 1
Étude du rôle des facteurs de transcription inducteurs d’EMT dans la mélanomagenèse
Richard, G. (2015) · theses.fr (ABES) · doi:10.70675/5e2b524dzca34z4777zb472z5368743bb211
Epigenetic regulation of gene expression during melanocyte and melanoma development
Laurette, P. (2016) · theses.fr (ABES) · doi:10.70675/b22b69c4z85a0z409czaccczc882ea46e923
Migault, M. (2017) · theses.fr (ABES) · doi:10.70675/55b7d871z6f9fz4039zaa17zaa0e82d57845
Metadata
- Authors
- Wellbrock, C., & Marais, R.
- Affiliations
- Institute of Cancer Research (GB)
- Corresponding author
- Marais, Richard
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2005-08-29
- Volume
- 170
- Issue
- 5
- Pages
- 703-708
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2171350
- OpenAlex
- W2169209908
- Cited by
- 196
- References
- 20
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 6 · 2022: 7 · 2021: 4 · 2020: 4 · 2019: 12 · 2018: 6 · 2017: 11 · 2016: 14 · 2015: 7 · 2014: 13 · 2013: 16 · 2012: 10
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Cell Biology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- MITF, BRAF, melanoma, melanocytes, cell proliferation, transcriptional regulation, melanocyte differentiation, melanoma progression
- MeSH terms
- Cyclic AMP, Animals, Cell Line, Cell Line, Transformed, DNA-Binding Proteins, Enzyme Activation, Humans, Melanocytes, Melanoma, Transcription Factors, Signal Transduction, Down-Regulation, RNA Interference, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, Microphthalmia-Associated Transcription Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.